ITGAX and infection: To better understand the effect of VX-765 treatment on inflammasome activation in immune cells subsets, we next investigated caspase-1 activity using the FAM-FLICA Caspase-1 assay reagent at day 23 post-infection in CD4+, CD8+, CD14+, and CD11c+ cells from the spleen and the bone marrow in VX-765 and vehicle-treated HIV-1 infected huNSG mice (Figure 7 and Figure 7—figure supplement 1).